The novel coronavirus disease 2019 (COVID-19) has caused an outbreak and become a major public health issue and great concern from international community. Cardiac injuries were suspected and may even be considered as one of the leading causes for death of COVID-19 patients, especially for those with cardiovascular (CV) risk factors. The aim of this study is to investigate if cardiac injury (CI) in COVID-19, preexisting or acquired, is associated to increased mortality in these patients from intensive care unit (ICU) in Mohammed VI hospital in Marrakech, Morocco, from March 20, 2020 to May 20, 2020. Fifty-two patients with laboratory-confirmed COVID-19 were included. Demographic, clinical and laboratory data were extracted from electronic medical records (EMR). 22.7% patients had CI, all of them developed a HF during COVID-19 course and have died. Among these patients with HF, 44% had comorbidities (vs 7.3% of patients without HF p < 0.05). They were older (61.1 years old vs 50.5), 44% had hypertension and diabetes. Preexisting CV disease was reported in 44% (vs 1%). In terms of laboratory findings, Tn-T (med: 231; 422; 10.3; 8.87; 97.28; 41.86; 59.2; 39.27; 68 pg/mL), Nt-proBNP (553;152; 3166; 134; 306; 17900; 2524; 59000; 450 UI/L), levels of C-reactive protein (med: 147 [106.4-240] vs 162 [5-508.3] mg/L) and electrolyte disturbances: hypokalemia (88% vs 86%, p< 0. 05). Early evaluation and monitoring of cardiac damage with distinct attention to the elderly and highest CV risk factors may identify patients with HF and contributed to decreased COVID-19 mortality.